3D Bioprinting of a Novel Marine Collagen for Use in Orthopaedic Regenerative Medicine

Bhanu Manickavasagam, Kevin Tetsworth
Bio Consultancy Pty Ltd, Queensland, Australia

Keywords: 3D bioprinting, marine collagen, orthopaedic, regenerative medicine, military

An estimated 60,000 US military personnel have been injured while serving in Iraq and Afghanistan, with over 80% of these injuries involving the musculoskeletal system. Because bone is principally composed of collagen there are a wide variety of applications for this material in orthopaedics. The North American collagen biomaterial market was valued at $992 million in 2015, and is estimated to reach $4.9 billion by 2021. Collagen has previously been derived from bovine or porcine sources, but these can carry pathogens including bovine spongiform encephalopathy, transmissible spongiform encephalopathy, and foot and mouth disease. Bio Consultancy Pty Ltd has developed a marine invertebrate Type 1 collagen biomaterial (MCol-B) to replace mammalian derived collagen, addressing safety, ethics, and regulatory concerns. In-vitro and in-vivo studies have shown that MCol-B is non-immunogenic, non-inflammatory, and supports cell growth. Compared to bovine collagen the physical and mechanical properties of MCol-B exhibits superior properties including strength, water uptake, and denaturation temperature. 3D bioprinting can potentially provide an inexpensive, rapid alternative to traditional implants. Bio Consultancy is currently developing a 3D bioprinted marine collagen (MCol-P) for use in orthopaedic regenerative medicine, with significant implications for the treatment of combat injuries.